Brian Sullivan, CEO and Co-Founder
Brian has over 25 years of experience founding and building successful technology companies. He was chairman and CEO of Sterilmed, a medical device company, from 2003 until its sale to Johnson & Johnson for $330 million in 2011. Previously he was cofounder and CEO of Recovery Engineering, a filtration company that he took public and subsequently sold to Proctor and Gamble for $265 million in 1999. He has received five U.S. patents and has three patents pending. He graduated magna cum laude with distinction from Harvard College with an A.B. degree in economics.
Lance Laing, Ph.D., Chief Science Officer and Co-Founder
Lance’s career spans more than 20 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from The Johns Hopkins University and completed a National Institutes of Health postdoctoral fellowship at Washington University Medical School. He has received 17 U.S. patents and has an additional 31 PCT patents pending. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals (purchased by Novartis), where he worked under Professor Peter Kim, the recently retired president of Merck Research Laboratories. Most recently, Lance served as an executive director for an international drug discovery and development company.
Lance has built a world-class science team that includes drug discovery, cell signaling, high-throughput drug screening, molecular oncology, and human primary cell culture scientists.
Vicky Hahne, CFO
Vicky has more than 20 years of financial leadership experience, including the past 10 years in the healthcare industry. Prior to joining Celcuity, Vicky served as Controller of Respiratory Technologies Inc., a medical device manufacturer. While at Respiratory Technologies, she played a key role in the due diligence process to sell the company to Koninklijke Philips. Prior to Respiratory Technologies, she served as Controller for Ability Network Inc., a healthcare information technology company. From September 2007 through June 2012, Vicky served as Controller of Sterilmed Inc., a medical device reprocessing company, where she played a key role in the sale of the company to Johnson & Johnson. Prior to these roles, Vicky held several senior financial positions at SimonDelivers Inc., including Chief Financial Officer. Vicky has extensive experience in early stage, high growth companies with responsibilities including financial controls and stewardship, financial analysis, mergers and acquisitions, building infrastructure and systems. She received a Bachelor of Science degree in Finance and Accounting from Northern State University and received her CPA certificate in 1990.
Laura Beggrow, RN, Chief Commercial Officer
Laura possesses more than 20 years of leadership experience in the bio-technology, pharmaceutical and molecular diagnostics industry. She has led numerous, successful product launches and her experience includes serving as President, Chief Commercial Officer and Vice President of Sales & Marketing of several molecular diagnostics companies. As the VP of Sales and Marketing at Genomic Health, she built and led a team of over 130 sales and marketing professionals that worked with medical oncologists and surgeons specializing in treating breast cancer. Laura’s current focus at Celcuity is laying the initial foundation for the successful commercialization of our first CELx tests. She received a Bachelor of Science in Nursing Degree from The Ohio State University.
Larry Fitzgerald, VP Strategic Partnerships & Managed Markets
Larry has over 18 years of experience working with oncology-oriented companies in the biotechnology, pharmaceutical, and molecular diagnostics industries, including Johnson & Johnson, Amgen, Novartis, Genomic Health, and InVitae. He has served in leadership roles in the sales, payor, and strategic accounts arena and has participated in the launch of a number of successful new drugs and molecular diagnostic tests. At Celcuity, Larry will initially focus on strategic collaborations and developing our payor strategy for our first CELx diagnostics. Larry received a Bachelor of Science in Finance from the University of Florida.